Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sasikanth Adigopula

Advanced Heart Failure and Transplant Cardiology Indianapolis, IN Medical Doctor

NPI 1053325050 CMS profile 735139

8075 N Shadeland Ave Ste 200, Indianapolis, IN 46250

Open in the dashboard

General payments

$310,239

308 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$892,333 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Sasikanth Adigopula of Indianapolis, IN is reported in the CMS Open Payments database as having received $310,239 across 308 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $892,333 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $118,352 101
2024 General $101,035 94
2023 General $68,272 58
2022 General $7,592 24
2021 General $7,909 10
2020 General $6,707 7
2019 General $372 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sasikanth Adigopula
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Sasikanth Adigopula were reported at $118,352. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Sasikanth Adigopula Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $372 $863 $224–$4,562 $163
2020 $6,707 $452 $122–$3,992 $114
2021 $7,909 $550 $159–$3,571 $132
2022 $7,592 $729 $221–$4,357 $149
2023 $68,272 $1,002 $309–$5,827 $160
2024 $101,035 $931 $273–$5,204 $164
2025 $118,352 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $130,352 73 payments
  2. Actelion Pharmaceuticals US, Inc. $54,165 74 payments
  3. AstraZeneca Pharmaceuticals LP $42,414 41 payments
  4. United Therapeutics Corporation $41,243 29 payments
  5. Lilly USA, LLC $21,185 16 payments
  6. Abbott Laboratories $11,468 27 payments
  7. Scpharmaceuticals Inc. $7,850 5 payments
  8. Boston Scientific Corporation $327 6 payments
  9. CVRx, Inc. $186 6 payments
  10. Novo Nordisk Inc $152 3 payments
  11. Other $897 28 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $268,400 99 payments
  2. Travel and Lodging $21,387 41 payments
  3. Consulting Fee $12,038 6 payments
  4. Food and Beverage $8,230 160 payments
  5. Education $184 2 payments
Products named General payments · program years 2019–2025
  1. JARDIANCE Diabetes $81,842 48 payments
  2. OPSUMIT $53,853 65 payments
  3. UPTRAVI $49,743 64 payments
  4. JARDIANCE Diabetes $48,509 25 payments
  5. FARXIGA $34,191 30 payments
  6. JARDIANCE Diabetes $21,185 16 payments
  7. LOKELMA $8,006 6 payments
  8. FUROSCIX $7,850 5 payments
  9. MITRACLIP $4,234 6 payments
  10. CardioMEMS HF System $3,448 5 payments
  11. Other $7,893 88 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

602

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$1,133,028

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

57.1%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Uptravi Selexipag Brand 12 $279,740
Vyndamax Tafamidis Brand 11 $237,705
Opsumit Macitentan Brand 13 $160,512
Camzyos Mavacamten Brand 20 $159,017
Jardiance Empagliflozin Brand 114 $96,073
Entresto Sacubitril/Valsartan Brand 78 $79,804
Farxiga Dapagliflozin Propanediol Brand 41 $44,521
Orenitram Er Treprostinil Diolamine Brand 12 $42,543
Eliquis Apixaban Brand 17 $16,789
Corlanor Ivabradine Hcl Brand 15 $12,310

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$28,615

Medicare's payments for the services billed

Medicare patients

162

Average age 73

Services billed

392

81 women, 81 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 64%
Chronic kidney disease 60%
Atrial fibrillation 57%
Diabetes 54%
Arthritis 48%
COPD 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $55,443
  • Lilly USA, LLC $7,514
$62,958 114 —
LOKELMA
  • AstraZeneca Pharmaceuticals LP $7,993
$7,993 — —
FUROSCIX
  • SCPHARMACEUTICALS INC. $7,850
$7,850 — —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $5,911
$5,911 13 —
TYVASO
  • United Therapeutics Corporation $1,969
$1,969 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

308 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record